Could stock splits be coming back in vogue? Apple finally announced a major stock split. What is amazing is that the split was so large, on a seven-for-one basis.
ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off of momentum stocks in a reality check. The problem is that after…
In a new report, the Credit Suisse team says large cap biotech is cheaper than the S&P 500 on 2016 and 2017 numbers. Here are the top biotech names rated Outperform at…
ThinkstockWhen the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index and immediately…
Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are looking for…
In a new report from RBC, its analysts say that biotech stocks trading at some of the lowest forward multiples in years are very attractive for many investors. Here are the top…
Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent on its top-selling multiple-sclerosis drug.
courtesy of Morgan StanleyLike many of its Wall Street peers, the brutal sell-off in the biotechnology space has Morgan Stanley taking a closer look at the top names. The firm initiated coverage…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, March 27, 2014. They include Apple, BlackBerry, Chesapeake Energy, Citigroup and King Digital.
For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress hit the sector hard. This may be a…
Many bears on Wall Street say that biotech stocks are overvalued, but many trade in line with historical valuations. In a new research report, Cowen highlights upcoming catalysts that could send some…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms in Thursday, March 6, 2014. The include Biogen Idec, Exxon Mobil, MarkWest Energy and Yum! Brands.
Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top…
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and…
Biogen Idec has announced that Chairman William D. Young will retire from the its board of directors and will be replaced by Stelios Papadopoulos. The latter is a former investment banker specializing…
Trey Thoelcke 
